WATCH TV LIVE

Tags: j&j | ambrx | cancer | johnson andjohnson

J&J to Buy Cancer Therapy Developer Ambrx for $2B

J&J to Buy Cancer Therapy Developer Ambrx for $2B
(Dreamstime)

Monday, 08 January 2024 08:22 AM EST

Johnson & Johnson said Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to its portfolio of targeted cancer therapies.

J&J will pay $28 per share of Ambrx, which represents a premium of about 105% to the stock's last close.

Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as "guided missiles" to target cancer cells and minimize damage to healthy tissue.

J&J's acquisition is the latest deal announced in the space. In November, AbbVie said it would buy ADC-developer ImmunoGen for $10.1 billion in cash.

© 2025 Thomson/Reuters. All rights reserved.


Click Here to comment on this article
Share
StreetTalk
Johnson & Johnson said Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to its portfolio of targeted cancer therapies.
j&j, ambrx, cancer, johnson andjohnson
105
2024-22-08
Monday, 08 January 2024 08:22 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved